Having trouble accessing articles? Reset your cache.

Budesonide MMX: Phase III data

Top-line data from the double-blind, U.S. and Indian Phase III CB-01-02/01 trial in 489 patients showed that once-daily 9 mg budesonide MMX met the primary endpoint of superiority to placebo

Read the full 302 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE